TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases. Researchers conclude that VB-201, the lead compound in a new class of drug candidates developed by VBL called Lecinoxoids, serves as proof of concept that anti-inflammatory phospholipids may offer a novel therapeutic approach for the treatment of immune-mediated disorders. The article appears in the December 2010 issue of the Current Opinion in Lipidology.
